Taysha Gene Therapies, Inc. (TSHA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.36+6.60%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · TSHA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“During the second quarter, we continued to execute against our clinical development strategy for TSHA-102 while advancing key commercial and manufacturing readiness initiatives in support of a poten…
Stated in 2 of 2 supplied quarters. Management reported: “Taysha completed dosing in the overenrolled REVEAL pivotal trial, with a total of 17 patients in the developmental plateau population of Rett syndrome dosed with TSHA-102.” “Subsequently, Taysha plans to discuss data from the 6-month interim analysis and next steps in the BLA submission pathway with the U.S. Food and Drug Administration (FDA) and is on track to report topline data and regulatory feedback in 1H 2027.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
““During the second quarter, we continued to execute against our clinical development strategy for TSHA-102 while advancing key commercial and manufacturing readiness initiatives in support of a poten…”
““We continued to execute our clinical development strategy for TSHA-102 and recently reaffirmed alignment with the FDA on our pathway to a BLA filing, including trial design, endpoints and the potent…”
Mr. Nolan continued, “We are working diligently to advance our commercial readiness activities to support the potential launch of TSHA-102, if approved.
Stated in 2 of 2 supplied quarters. Management reported: “The agreement establishes a long-term commercial supply framework intended to support commercial launch and future demand.” “High dose (1x10 15 total vg) and low dose (5.7x10 14 total vg) TSHA-102 continue to be generally well tolerated with no severe treatment-related serious adverse events (SAEs) or dose limiting toxicities (DLTs) in all patients treated in the REVEAL Phase 1/2, REVEAL pivotal and ASPIRE trials (N=33) as of the August 2026 data cutoff.”
“Mr. Nolan continued, “We are working diligently to advance our commercial readiness activities to support the potential launch of TSHA-102, if approved.”
“The increase of $1.5 million was primarily due to higher compensation expenses, including non-cash stock-based compensation expense, and increases in consulting and professional fees, including comme…”
The Company expects that its current cash resources will support planned operating expenses and capital requirements into the second half of 2028.
Stated in 2 of 2 supplied quarters. Management reported: “Proceeds included full exercise of the underwriters’ option to purchase additional shares; anticipated cash runway extends into the second half of 2028 and through potential BLA approval of TSHA-102.” “Cash and Cash Equivalents: As of June 30, 2026, Taysha had $455.4 million in cash and cash equivalents.”
“The Company expects that its current cash resources will support planned operating expenses and capital requirements into the second half of 2028.”
“The Company expects that its current cash resources will be sufficient to fund planned operating expenses into 2028.”
Continue to show TSHA-102 is generally well tolerated with no severe treatment-related serious adverse events or dose-limiting toxicities across trials.
Continue clinical trials and regulatory engagement for TSHA-102 gene therapy in Rett syndrome, including pivotal and safety trials and BLA submission preparation.
Over the trailing year it converted 2.45x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
4 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-04.